We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

PATH -2 Study reaches target!

THE PATH-2 Study is a trial of platelet rich plasma (PRP) as a non-surgical treatment for Achilles tendon rupture. PRP is blood plasma containing a high concentration of platelets, specialised blood cells involved in wound repair. Eligible patients are randomised to receive standard non-operative care, or standard care plus PRP injection. Our primary outcome is an objective test of ankle function conducted at 6 months after treatment by a blinded physiotherapist assessor. This is the first large double-blinded randomised controlled trial of PRP in tendons.

In September 2017 the PATH-2 Study reached its target of 230 participants, recruited at outpatient clinics in 18 hospitals in England and Wales. PATH-2 is funded by EME, a partnership of the National Institute for Health Research and the Medical Research Council (EME reference 12/206/30).